94 related articles for article (PubMed ID: 20678118)
1. Effects of acetyl-L-carnitine and oxfenicine on aorta stiffness in diabetic rats.
Chang KC; Tseng CD; Lu SC; Liang JT; Wu MS; Tsai MS; Hsu KL
Eur J Clin Invest; 2010 Nov; 40(11):1002-10. PubMed ID: 20678118
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-l-carnitine and oxfenicine on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar rats.
Wang CH; Wang SS; Ko WJ; Chen YS; Chang CY; Chang RW; Chang KC
PLoS One; 2013; 8(7):e69977. PubMed ID: 23922880
[TBL] [Abstract][Full Text] [Related]
3. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
Schmitz FJ; Rösen P; Reinauer H
Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
[TBL] [Abstract][Full Text] [Related]
4. [The action of carnitine-series preparations in experimental alloxan diabetes mellitus].
Kim EK; Trevisani C; Trevisani M
Eksp Klin Farmakol; 1992; 55(4):35-6. PubMed ID: 1458184
[TBL] [Abstract][Full Text] [Related]
5. Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta.
Irat AM; Aktan F; Ozansoy G
J Pharm Pharmacol; 2003 Oct; 55(10):1389-95. PubMed ID: 14607021
[TBL] [Abstract][Full Text] [Related]
6. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
Nakamura J; Koh N; Sakakibara F; Hamada Y; Hara T; Sasaki H; Chaya S; Komori T; Nakashima E; Naruse K; Kato K; Takeuchi N; Kasuya Y; Hotta N
J Pharmacol Exp Ther; 1998 Dec; 287(3):897-902. PubMed ID: 9864270
[TBL] [Abstract][Full Text] [Related]
7. Altered neuroexcitability in experimental diabetic neuropathy: effect of acetyl-L-carnitine.
Malone JI; Lowitt S; Corsico N; Orfalian Z
Int J Clin Pharmacol Res; 1992; 12(5-6):237-41. PubMed ID: 1301404
[TBL] [Abstract][Full Text] [Related]
8. Aminocarnitine ureidic derivatives as inhibitors of carnitine palmitoyltransferase I.
Tassoni E; Conti R; Gallo G; Vincenti S; Dell'Uomo N; Mastrofrancesco L; Ricciolini R; Cabri W; Carminati P; Giannessi F
ChemMedChem; 2010 May; 5(5):666-9. PubMed ID: 20232438
[No Abstract] [Full Text] [Related]
9. Effect of acetyl-L-carnitine treatment on the levels of levocarnitine and its derivatives in streptozotocin-diabetic rats.
Marzo A; Corsico N; Cardace G; Morabito E
Arzneimittelforschung; 1993 Mar; 43(3):339-42. PubMed ID: 8489564
[TBL] [Abstract][Full Text] [Related]
10. Reduced effects of L-carnitine on glucose and fatty acid metabolism in myocytes isolated from diabetic rats.
Abdel-aleem S; Karim AM; Zarouk WA; Taylor DA; el-Awady MK; Lowe JE
Horm Metab Res; 1997 Sep; 29(9):430-5. PubMed ID: 9370110
[TBL] [Abstract][Full Text] [Related]
11. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
[TBL] [Abstract][Full Text] [Related]
12. Co-administration of etomoxir and RU-486 mitigates insulin resistance in hepatic and muscular tissues of STZ-induced diabetic rats.
Bitar MS
Horm Metab Res; 2001 Oct; 33(10):577-84. PubMed ID: 11607876
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.
Giannessi F; Pessotto P; Tassoni E; Chiodi P; Conti R; De Angelis F; Dell'Uomo N; Catini R; Deias R; Tinti MO; Carminati P; Arduini A
J Med Chem; 2003 Jan; 46(2):303-9. PubMed ID: 12519067
[TBL] [Abstract][Full Text] [Related]
14. Serum and urine levels of levocarnitine family components in genetically diabetic rats.
Morabito E; Corsico N; Marzo A; Arrigoni Martelli E
Arzneimittelforschung; 1994 Aug; 44(8):965-8. PubMed ID: 7945543
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals.
Di Giulio AM; Gorio A; Bertelli A; Mantegazza P; Ferraris L; Ramacci MT
Int J Clin Pharmacol Res; 1992; 12(5-6):243-6. PubMed ID: 1284499
[TBL] [Abstract][Full Text] [Related]
16. Influence of carnitine acyltransferase inhibitors on the performance and metabolism of rat cardiac muscle.
Reinauer H; Adrian M; Rösen P; Schmitz FJ
J Clin Chem Clin Biochem; 1990 May; 28(5):335-9. PubMed ID: 2380671
[TBL] [Abstract][Full Text] [Related]
17. Effect of L-carnitine on diabetogenic action of streptozotocin in rats.
Uysal N; Yalaz G; Acikgoz O; Gonenc S; Kayatekin BM
Neuro Endocrinol Lett; 2005 Aug; 26(4):419-22. PubMed ID: 16135998
[TBL] [Abstract][Full Text] [Related]
18. Counteraction on experimentally induced diabetic neuropathy by levocarnitine acetyl.
Pacifici L; Bellucci A; Piovesan P; Maccari F; Gorio A; Ramacci MT
Int J Clin Pharmacol Res; 1992; 12(5-6):231-6. PubMed ID: 1301403
[TBL] [Abstract][Full Text] [Related]
19. Peptide alterations in autonomic diabetic neuropathy prevented by acetyl-L-carnitine.
Gorio A; Di Giulio AM; Tenconi B; Donadoni L; Germani E; Bertelli A; Mantegazza P; Maccari F; Ramacci MT
Int J Clin Pharmacol Res; 1992; 12(5-6):225-30. PubMed ID: 1284498
[TBL] [Abstract][Full Text] [Related]
20. Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain.
Alves E; Binienda Z; Carvalho F; Alves CJ; Fernandes E; de Lourdes Bastos M; Tavares MA; Summavielle T
Neuroscience; 2009 Jan; 158(2):514-23. PubMed ID: 19015003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
